ArticlePloS one2025
Liver-related outcomes in patients with cirrhosis: The value of clinical and laboratory data and noninvasive tests.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical and laboratory characteristics associated with ascites in patients with MASLD-related cirrhosis: a cross-sectional study.Translational gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeCirrhosis patients face high mortality risks from complications, emphasizing the need for prognostic tools to estimate risk of adverse liver outcomes based on cirrhosis etiology and hence improve disease management. This study aimed to evaluate the association between baseline clinical factors, lab values and noninvasive measurements and risk of adverse liver outcomes among patients with cirrhosis, and develop disease-specific associative models.
methodsUsing proportional hazards regression, we developed six associative models, categorized by cirrhosis etiology, after identifying significant predictors of 30-day risk of ascites, hepatic encephalopathy (HE), and variceal bleeding (VB) among cirrhosis patients, with measurements selected through LASSO regression.
resultsA total of 4045 adult patients with cirrhosis were included in the analysis from a single U.S. center retrospective cohort. The 5-year rates for ascites, HE, and VB were 31.6%, 22.9%, and 30.7%, respectively. Multivariable analyses showed that independent predictors in cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) and viral hepatitis were: (a) ascites: albumin and international normalized ratio (INR); (b) HE: albumin, INR, total bilirubin, platelet count; (c) VB: albumin, platelet count, hemoglobin. No variables were significantly associated with outcomes in patients with alcohol-associated liver disease.
conclusionsThe newly developed models provided accurate estimates of the 30-day risks of ascites, HE, and VB in MASH or viral hepatitis-related cirrhosis using baseline variables, providing a reliable tool for identifying high-risk patients warranting intensified interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.